Global Radiopharmaceuticals Industry

·25 min read

NEW YORK, Nov. 23, 2020 /PRNewswire/ --
Sharp Decline in Patient Throughput in Imaging Centers Due to COVID-19 Outbreak Induces a -6.3% Erosion in Demand for Radiopharmaceuticals


Read the full report: https://www.reportlinker.com/p01591554/?utm_source=PRN


The global market for Radiopharmaceuticals is expected to slump by -6.3% in the year 2020 and thereafter recover to reach US$9.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.4% over the analysis period 2020 through 2027. The healthcare supply chain is navigating unchartered, rough waters and struggling to maintain pace with rapidly increasing cases of COVID-19. The pandemic has devastated nearly all segments associated with the healthcare sector, such as medical devices, pharmaceuticals and essential supplies. Healthcare organizations globally are finding it extremely challenging to serve patients while ensuring safety of the medical staff due to marked shortage of supplies as a result of supply chain disruptions. The scenario is complicated by unprecedented scale of the pandemic along with few sourcing options and export restrictions. Amid the COVID-19 outbreak, most companies have reported some form of disruption in their supply chains owing to transportation restrictions. The crisis has also resulted in supply issues associated with radiopharmaceuticals, radioisotopes and kits for therapeutic and diagnostic applications. Nuclear medicine and personalized medicine are heavily reliant on the timely availability of radioisotopes. With air freight restrictions imposed, transport of Mo-99, Tc-99m and other radioisotopes remains impacted during COVID times. NTP Radioisotopes is currently operating at below normal capacity as a result of logistical challenges in South Africa.

While the US accounts for nearly half of the market, it relies on three suppliers of Molybdenum-99 and Technetium-99m. In addition, majority of African nations depend heavily on a single supplier of these radioisotopes that are used for cancer imaging. The COVID-19 outbreak has complicated the scenario owing to ongoing restrictions on flights that have severely disrupted global supply chains, prompting participants to ensure reliable radiopharmaceuticals supply for nuclear medicine. Participants are also facing issues in procuring cold kits for simplifying radiopharmaceutical production. These supply constraints along with shortage of qualified staff has made it challenging for countries to perform tasks such as labeling and quality assurance, hampering complex procedures. There are issues related to particular radiopharmaceuticals. While 18F-FDG is extensively used, non-FDG tracers remained in limited quantities across low-income nations owing to their extensive nature, regulatory restrictions and lack of cyclotron. In addition, various countries are unable to access therapeutic tracers including 123I, 123I-MIBG, and 131I-MIBG due to supply and cost issues. The scenario remains challenging for non-COVID-19 treatment solutions such as medical radioisotopes, which are used in diagnosis and treatment of cancer and certain health conditions by healthcare providers around the world. Every year, millions of patients are administered with radioisotopes for diagnosis and therapeutic purposes. With governments defining the medical radioisotope production facilities as 'essential', production operations continued during the COVID-19 pandemic period. Reactors engaged in production of radioisotopes remained operational in compliance with the relevant IAEA safety standards and in adherence to relevance measures to prevent the effects and spread of COVID-19 disease. Reactors based out of Argentina, Australia, Belgium, Czech Republic, Netherlands, Poland, Russia , USA, and South Africa, account for almost the entire world production of radioisotopes, and the radio compounds produced in these countries are transported worldwide mainly via aerial route.

In the post pandemic period, pent-up demand for cancer and other chronic diseases will push up demand for radioisotopes. The huge unmet needs and the ensuing massive opportunity for imaging technologies and services will benefit long-term growth of radiopharmaceuticals. Growth during this period will continue to benefit from the growing mainstream interest in nuclear medicine, and the development of new radionuclide's for cancer nuclear imaging and internal radiotherapy. A key trend of the pre-virus period that will emerge to spur gains is the shifting of healthcare from fee based systems to value based systems and the resulting new commercial value placed on hybrid molecular imaging techniques which utilize radiopharmaceuticals for accurate and early disease diagnosis. Development of new and innovative radiopharmaceuticals has and will continue to spur the use of PET/CT and SPECT/CT imaging platforms across new clinical areas including cardiology, neurology, orthopedics, pulmonology and oncology. The epidemic spread of cancer will fuel interest in non-invasive tumor receptor imaging thereby pushing up the significance of molecular imaging for its ability to enable better understanding of tumor biology so as to develop more personalized and targeted treatment regimes. Other growth drivers will include growing incidence of cardiovascular diseases and new launch of cardiac radiopharmaceuticals such as flurpiridaz f-18 and ammonia n-13 in the field of cardiovascular disease imaging; expected developments in non-reactor based production of tc-99m in a bid to overcome production challenges of Tc-99m; growing population and healthcare burden; pressing need for effective healthcare solutions; government policy led focus on healthcare infrastructure development; and concerted efforts taken to promote nuclear medicine in emerging Asian economies grappling with the economic challenges of providing affordable healthcare.

Competitors identified in this market include, among others,

  • Actinium Pharmaceuticals Inc.

  • Alliance Medical

  • Alseres Pharmaceuticals Inc.

  • Avid Radiopharmaceuticals

  • Bayer HealthCare, Radiology Division

  • Bracco Diagnostics Inc.

  • Cardinal Health, Inc.

  • GE Healthcare

  • Immunomedics, Inc.

  • Ion Beam Applications SA

  • Jubilant Pharma

  • Lantheus Medical Imaging Inc.

  • Medi-Radiopharma Ltd.

  • Nordion, Inc.

  • Peregrine Pharmaceuticals, Inc.

  • PETNET Solutions Inc.

  • Positron Corporation

  • Triad Isotopes Inc.





Read the full report: https://www.reportlinker.com/p01591554/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
COVID-19-Led Disruptions Exhaust Radiopharmaceuticals Supply to
Hinder Nuclear Medicine Procedures in Most Countries II-2
Exhibit 1: Imaging Screening Volume % Change 1H 2019 Vs 1H 2020
in U.S Hospitals II-3
Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals
Struggling with Seamless Supply of Medical Radioisotopes II-3
Nuclear Medicine Services Limp Back to Normality after Easing
of COVID-19 Restrictions II-4
COVID-19 Presents Generational Opportunity II-5
Radiopharmaceuticals: A Prelude II-5
Mechanism of Action II-6
Global Supply Shortages Continue to Challenge Market Growth II-6
Exhibit 2: A Glimpse at Mo-99 Processors Worldwide II-8
Exhibit 3: Nuclear Research Reactor Irradiators Worldwide: A
Snapshot II-9
Outlook II-9
Key Market Drivers II-10
Market Restraints II-11
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance II-13
Classification of Radiopharmaceuticals II-13
Diagnostic Radiopharmaceuticals: The Dominant Segment II-13
Key Drivers II-14
Positron Emission Tomography (PET) II-15
Major PET Isotopes and their Applications II-16
Single Photon Emission Computed Tomography (SPECT) II-16
Major Isotopes and their Diagnostic Applications II-17
Therapeutic Radiopharmaceuticals II-18
Select Isotopes and their Therapeutic Applications II-18
Key Drivers II-18
Competitive Landscape II-19
Exhibit 4: Radiopharmaceuticals Competitor Market Share
Scenario Worldwide (in %): 2019 II-19
Recent Industry Activity II-20
World Brands II-23

2. FOCUS ON SELECT PLAYERS II-24

3. MARKET TRENDS & DRIVERS II-26
Emergence of Radiotheranostics: Dual-Functioning
Radiopharmaceuticals II-26
Changing Role of Radiopharmaceuticals in Diagnostic and
Therapeutic Applications II-26
Advent of New Radiopharmaceuticals Widen Scope II-27
Select New Products II-28
Industry Focus Gears up for Innovative Radiopharmaceuticals
with Therapeutic Benefits II-28
Select Commercially Available Therapeutic Radiopharmaceuticals II-29
PET Eclipses SPECT in Cardiovascular Imaging II-30
Exhibit 5: Worldwide Installed Base of Nuclear Imaging
Equipment by Modality, PET Vs SPECT: 2019 II-30
Cardiac Amyloidosis Visualization: A Potential Application for PET II-31
Innovative Radiopharmaceuticals to Boost Cardiac Applications II-31
Exhibit 6: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others II-32
Application of PET in Drug Development to Expand Opportunities II-32
Intra-operative Lymphatic Mapping (ILM): Creates New
Opportunities for Radiopharmaceuticals in Cancer Detection II-33
Personalized Medicine Drives Nuclear Medicine II-34
Exhibit 7: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population II-35
Exhibit 8: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024 II-36
Rise in Incidence of Neurological Disorders to Drive Growth II-36
Rising Cancer Incidence Worldwide Spurs Demand II-37
Exhibit 9: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-38
Exhibit 10: Global Number of New Cancer Cases and Cancer-
related Deaths by Cancer Site for 2018 II-39
Exhibit 11: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018 II-40
Ageing Population: A Vital Demography II-40
Exhibit 12: Global Aging Population: Population of 65+
Individuals (in Thousands) by Region for 2019 and 2030 II-41
Exhibit 13: Global Cancer Deaths by Age Group (in %) for 2019 II-42
Rise in Healthcare Expenditure to Drive Growth II-42
Exhibit 14: Elderly Healthcare Expenditure as a % of GDP II-44
Exhibit 15: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023 II-44
Relevant Aspects of Radiopharmaceutical Production II-45
Regulatory Regime Governing Production and Use of
Radiopharmaceuticals II-45

4. GLOBAL MARKET PERSPECTIVE II-47
Table 1: World Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-47

Table 2: World Historic Review for Radiopharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-48

Table 3: World 11-Year Perspective for Radiopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2016, 2020 & 2027 II-49

Table 4: World Current & Future Analysis for SPECT
Radioisotopes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-50

Table 5: World Historic Review for SPECT Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-51

Table 6: World 11-Year Perspective for SPECT Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-52

Table 7: World Current & Future Analysis for PET Radioisotopes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-53

Table 8: World Historic Review for PET Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-54

Table 9: World 11-Year Perspective for PET Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-55

Table 10: World Current & Future Analysis for Beta Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-56

Table 11: World Historic Review for Beta Emitters by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-57

Table 12: World 11-Year Perspective for Beta Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-58

Table 13: World Current & Future Analysis for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-59

Table 14: World Historic Review for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-60

Table 15: World 11-Year Perspective for Alpha Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-61

Table 16: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-62

Table 17: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-63

Table 18: World 11-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-64

Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-65

Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-66

Table 21: World 11-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2020 & 2027 II-67

Table 22: World Current & Future Analysis for Cardiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-68

Table 23: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-69

Table 24: World 11-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-70

Table 25: World Current & Future Analysis for Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-71

Table 26: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 II-72

Table 27: World 11-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2020 & 2027 II-73

Table 28: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-74

Table 29: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-75

Table 30: World 11-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-76

Table 31: World Current & Future Analysis for Hospitals &
Diagnostic Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-77

Table 32: World Historic Review for Hospitals & Diagnostic
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2016 through 2019 II-78

Table 33: World 11-Year Perspective for Hospitals & Diagnostic
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2020 &
2027 II-79

Table 34: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-80

Table 35: World Historic Review for Ambulatory Surgical Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-81

Table 36: World 11-Year Perspective for Ambulatory Surgical
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2020 &
2027 II-82

Table 37: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-83

Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 II-84

Table 39: World 11-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027 II-85

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1
Market Overview III-1
Diagnostic Applications Stimulate Future Growth III-1
Demographic Changes Offer Growth Opportunities III-2
Exhibit 16: US Elderly Population: Expected Growth Rates Over
the Years 2005-2025 III-2
Rising Incidence of Cancer: A Major Growth Driver III-3
Exhibit 17: Leading Sites of New Cancer Cases in Males: 2020 III-3
Exhibit 18: Leading Sites of New Cancer Cases in Females: 2020 III-4
Cardiovascular Imaging to Lead Volume Growth III-4
Radiopharmaceuticals Usage Strengthens in PET Imaging III-5
Radioisotope/Radiopharmaceuticals Supply Scenario III-6
Passing of Medicare Diagnostic Radiopharmaceutical Payment
Equity Act III-7
Market Analytics III-8
Table 40: USA Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-8

Table 41: USA Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-9

Table 42: USA 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-10

Table 43: USA Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-11

Table 44: USA Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-12

Table 45: USA 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027 III-13

Table 46: USA Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-14

Table 47: USA Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-15

Table 48: USA 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-16

CANADA III-17
Market Overview III-17
Efforts on to Address Mo-99 Supply Shortage III-17
Market Analytics III-18
Table 49: Canada Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-18

Table 50: Canada Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-19

Table 51: Canada 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-20

Table 52: Canada Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-21

Table 53: Canada Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-22

Table 54: Canada 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2020 & 2027 III-23

Table 55: Canada Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-24

Table 56: Canada Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-25

Table 57: Canada 11-Year Perspective for Radiopharmaceuticals
by End-Use - Percentage Breakdown of Value Sales for Hospitals
& Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-26

JAPAN III-27
Market Overview III-27
Market Analytics III-28
Table 58: Japan Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-28

Table 59: Japan Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-29

Table 60: Japan 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-30

Table 61: Japan Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-31

Table 62: Japan Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-32

Table 63: Japan 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027 III-33

Table 64: Japan Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-34

Table 65: Japan Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-35

Table 66: Japan 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-36

CHINA III-37
Market Overview III-37
Market Analytics III-37
Table 67: China Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-37

Table 68: China Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-38

Table 69: China 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-39

Table 70: China Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-40

Table 71: China Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-41

Table 72: China 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027 III-42

Table 73: China Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-43

Table 74: China Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 III-44

Table 75: China 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027 III-45

EUROPE III-46
Market Overview III-46
Market Analytics III-47
Table 76: Europe Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 III-47

Table 77: Europe Historic Review for Radiopharmaceuticals by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2016 through 2019 III-48

Table 78: Europe 11-Year Perspective for Radiopharmaceuticals
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2016, 2020 & 2027 III-49

Table 79: Europe Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-50

Table 80: Europe Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 III-51

Table 81: Europe 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027 III-52

Table 82: Europe Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027 III-53

Table 83: Europe Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 III-54

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p01591554/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/global-radiopharmaceuticals-industry-301178757.html

SOURCE Reportlinker

Latest Stories

  • Republican lawmaker calls for Kyle Rittenhouse, who is on trial for murder, to be elected to Congress

    Anthony Sabatini’s comment sparks demands for his resignation

  • Biden reportedly could sacrifice unemployment benefit boost to secure relief bill

    Incoming presidents "typically want to wait until they have the reins of power in order to put their fingerprints on the policies coming out of the door," Jared Bernstein, who served as President-elect Joe Biden's chief economist during the Obama administration, said this week during a virtual conference. But, he added, Biden would prefer that not be the case when it comes to coronavirus relief, which is "something that should happen now."Biden has entered the coronavirus relief fight and wants a deal done before he's sworn in as president, Politico reports, even though waiting would theoretically increase the Democratic Party's chances of securing a larger deal, which is currently a non-starter for Senate Majority Leader Mitch McConnell (R-Ky.). "They care more about governing than they care about politics on this one," one person in touch with the transition team told Politico.Biden's camp is reportedly focused on ensuring Black-owned businesses receive loans they had trouble securing following the first relief bill, getting funding for state and local governments, and extending enhanced unemployment benefits. The latter issue is where Biden "may have to give something up to McConnell that we really don't want to give up to get" a deal, "but we simply have to do this," another person close to the transition team said. Read more at Politico.More stories from theweek.com There's a very simple, extremely plausible reason Trump won't admit Biden won I was wrong about Mitt Romney Biden is stealing the spotlight. Trump can't stand it.

  • Israel strikes Hamas sites in Gaza Strip after rocket attack

    Israeli aircraft on Sunday struck multiple sites in the Gaza Strip in response to a rocket fired earlier from the Palestinian territory, Israel's military said. While several militant groups operate out of the Palestinian enclave, Israel holds Gaza’s Hamas rulers responsible for all rocket fire out of the territory and usually strikes Hamas targets in response. The Israeli military said in a statement that fighter jets and attack helicopters hit two rocket ammunition manufacturing sites, underground infrastructure and a Hamas naval forces training compound.

  • Trump supporter who ‘forcefully exhaled’ on protesters faces charges, Virginia cops say

    The incident was caught on video.

  • 'He's irreplaceable': 21-year-old leader of Breonna Taylor protests killed in shooting, family says

    Hamza "Travis" Nagdy, a young protest leader during Louisville's movement for racial justice in 2020, was killed in a shooting, his family says.

  • Republicans dash to defend perilous 2022 Senate map

    GOP leadership is moving quickly to lock down incumbents in key swing states.

  • Maryland Gov. Larry Hogan is 'embarrassed' his GOP is helping Trump make the U.S. look like 'a banana republic'

    Maryland Gov. Larry Hogan (R) is no longer sure Trump will "do the right thing" and acknowledge his loss to President-elect Joe Biden, but he's certain Biden will be sworn in Jan. 20, 2021, he told CNN's Jake Tapper on Sunday's State of the Union. Hogan, who has been critical of Trump, said he voted for the late President Ronald Reagan this year.Pressuring state legislators in Michigan and other states to "somehow change the outcome with electors was completely outrageous," Hogan said. "We used to go supervise elections around the world, and we were the most respected country with respect to elections. And now we're beginning to look like we're a banana republic. It's time for them to stop the nonsense. It gets more bizarre every single day, and frankly, I'm embarrassed that more people in the party aren't speaking up."> Maryland Gov. Larry Hogan says he is "embarrassed that more people in the party aren't speaking up" regarding President Trumps' refusal to concede https://t.co/2wEl0kWIoX CNNSOTU pic.twitter.com/ht8v9oi0O5> > -- CNN Politics (@CNNPolitics) November 22, 2020John Bolton, Trump's former national security adviser, was also critical of both Trump and his Republican Party, but he did offer some advice to those Republican officials scared of Trump. "Look, for those who are worried about Trump's reaction, there's strength in numbers," he said. "The more who come out and say, 'He doesn't represent us, he is not following a Republican game plan here,' the safer they will be." > "The Republican Party is not going to be saved by hiding in a spider hole. We need all of our leaders to come out and say, 'the election is over.' We're not talking about an abstract right for Trump to use his legal remedies. We've past that," John Bolton says. CNNSOTU pic.twitter.com/pUFsiFj7PC> > -- State of the Union (@CNNSotu) November 22, 2020More stories from theweek.com There's a very simple, extremely plausible reason Trump won't admit Biden won I was wrong about Mitt Romney Biden is stealing the spotlight. Trump can't stand it.

  • Iowa congressman notorious for racist remarks asks Kamala Harris if she was descended from slave owners

    Outgoing Republican Steve King has long history of offensive remarks

  • Republican Sen. Kelly Loeffler, a candidate in the Georgia runoff, tested positive for COVID-19 and is quarantining

    Loeffler is currently campaigning in a high-stakes race that could determine control of the Senate at the start of President-elect Joe Biden's term.

  • Judge Finds the Fatal Flaw in Trump Campaign’s Pennsylvania Case

    A    federal court has thrown out the Trump campaign’s lawsuit in Pennsylvania, which challenged presumptive President-elect Joe Biden’s victory in the commonwealth. In so doing, district judge Matthew Brann refused the campaign’s eleventh-hour attempt to file a new complaint that would have reinstated election fraud claims the Trump campaign had abandoned a few days earlier. (I outlined the lawsuit here, and explained the Trump campaign’s last-ditch effort to amend it here.)Judge Brann’s 37-page opinion sets forth a variety of reasons for dismissing the case. Most of them are directed toward the complaints of two individual plaintiffs — voters who claimed that their ballots had been improperly discounted. By contrast, the court found that the Trump campaign had no standing to sue, having posited no evidence that President Trump was harmed in any cognizable way by the manner in which the election was conducted in Pennsylvania.At bottom, though, the court found that the fatal flaw in the case is the one that we have repeatedly stressed: The mismatch between the harm alleged and the remedy sought.As the judge explained, even if one accepted the dubious premise that the two voters in question were improperly denied the right to vote while others similarly situated were not, the commensurate relief would be for their votes to be counted.That, however, was not the remedy they sought. Instead, supported by the Trump campaign, the two voters petitioned the court to stop Pennsylvania from certifying — on Monday as state law requires — the commonwealth’s election result, which had Biden winning by 83,000 votes. Brann countered:> Prohibiting certification of the election results would not reinstate the Individual Plaintiffs’ right to vote. It would simply deny more than 6.8 million [Pennsylvanians] their right to vote. “Standing is measured based on the theory of harm and the specific relief requested.” It is not “dispensed in gross: A plaintiff's remedy must be tailored to redress the plaintiff's particular injury.” Here, the answer to invalidated ballots is not to invalidate millions more. [Footnotes omitted.]As we detailed on Friday, the case was in a strange posture.In filing its original complaint on November 9, the Trump campaign claimed extensive vote fraud, relying mainly on the allegation that Republican poll-watchers had been denied a meaningful opportunity to observe the canvassing of ballots. But, as Brann notes (and we discussed here), on November 13, the federal appeals court for the Third Circuit (which has binding effect on Brann’s district court) issued its opinion in Bognet v. Secretary of the Commonwealth of Pennsylvania. Though not directly connected to the campaign’s case, Bognet’s reasoning substantially undercut its claims.The campaign reacted by amending its complaint, reducing the case to the narrow claim that Trump voters’ equal-protection rights (and, derivatively, the campaign’s rights) had been violated by an allegedly skewed procedure: Mail-in voters in Biden-friendly counties had been permitted to cure defects in the ballots they’d submitted, while voters in Trump-friendly counties were not. Brann rejected this claim, accepting Pennsylvania’s argument that Secretary of State Kathy Boockvar had encouraged ballot curing all over the state. Thus the state government was not at fault if not all counties availed themselves of this opportunity.That is largely beside the point, though. Even if there had been a violation of the voters’ rights, the remedy would be to count their votes. Instead, as the court observed,> Plaintiffs seek to remedy the denial of their votes by invalidating the votes of millions of others. Rather than requesting that their votes be counted, they seek to discredit scores of other votes, but only for one race [i.e., the presidential race, not the other contests down-ballot]. This is simply not how the Constitution works. [Emphasis added.]Moreover:> Granting Paintiffs’ requested relief would necessarily require invalidating the ballots of every person who voted in Pennsylvania. Because this Court has no authority to take away the right to vote of even a single person, let along millions of citizens, it cannot grant Plaintiffs’ requested relief.Brann concluded that the Trump campaign had no standing to sue based, derivatively, on the harm alleged by the two voters, particularly after the Bognet ruling. He specifically rejected both of the campaign’s main equal-protection complaints: (1) that its poll-watchers were discriminatorily excluded from observing the canvass, and (2) that the opportunity for voters to cure defective ballots was deliberately done in counties the state knew to favor Biden.On the former, Brann held that this was not, as the Trump campaign maintained, an equal-protection issue. The campaign was not claiming that Trump observers were treated differently from Biden observers. On the latter, Brann concluded that the campaign was misinterpreting Bush v. Gore, and, in any event, was not claiming that Boockvar’s guidance on curing ballots differed from county to county.Most significantly, Brann denied the Trump campaign’s dilatory attempt to amend its complaint yet again late this past week, in order to reinstate claims from their original complaint, which they’d withdrawn last weekend. The court reasoned that this would “unduly delay resolution of the issues” in light of the fact that Monday, November 23, is the deadline for Pennsylvania counties to certify their election results to the state government — a necessary prelude to appointing the slate of electors who will cast the commonwealth’s Electoral College votes.In reaction to the ruling, the Trump campaign lawyers issued a statement asserting that, though they disagreed with the decision by “the Obama-appointed judge,” it was actually a boon to “our strategy to get expeditiously to the U.S. Supreme Court.”It is true that Brann was appointed by former President Barack Obama, but he is a Republican and Federalist Society member who was sponsored by the state’s Republican senator Pat Toomey — a common situation when a state’s two senators are from different parties, and an administration has to horse-trade on appointments.Trump lawyers added that the ruling denied them “the opportunity to present our evidence at a hearing.” They described that as “censorship” of “50 witnesses” who would have testified that state election officials denied the “independent review” required by Pennsylvania law. This is an apparent reference to the campaign’s claim that its poll-watchers were not given a meaningful opportunity to observe the canvass, which the lawyers say, “resulted in 682,777 ballots being cast illegally.” The campaign did not mention that it had dropped this charge from its original complaint. Nor did it allude to Brann’s conclusion that the allegation was not a cognizable equal-protection claim under federal law.The campaign says it will seek an expedited appeal to the Third Circuit — the tribunal that just decided the Bognet case, the precedent that appears to have induced the campaign to withdraw the claims it is now seeking to revive. In any event, it is anything but clear that the Supreme Court, which has thus far declined to act on Pennsylvania election-law claims relevant to the 2020 election, would agree to hear the campaign’s case — even assuming that the Third Circuit grants expedited appeal and, as even the campaign plainly expects, rules against the campaign.

  • AstraZeneca vaccine by the University of Oxford is said to be '90% effective'

    AstraZeneca said Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease.

  • White House vaccine czar expects kids will receive coronavirus vaccine by middle of 2021

    There's a growing likelihood that the first round of Pfizer's coronavirus vaccine will be rolled out in just a few weeks. If and when that happens, only high priority groups, like health care workers, are expected to have access. Theoretically, the pool will grow over time, but children will probably have to wait a while. That's partly because younger people, though far from invulnerable to COVID-19, are less susceptible to severe cases, but it also has to do with the fact that the youngest people to receive Pfizer's candidate in trials were between 12 and 14 years old, Dr. Moncef Slaoui, the White House vaccine czar, told CNN's Jake Tapper on Sunday.As things stand, there's no data about the vaccine's efficacy or safety for younger children, but Slaoui says the plan is to run trials at an expedited pace over the coming months, first with younger adolescents, then toddlers, and, finally, infants. If that goes well, Slaoui, expects most kids will be able to get vaccinated by the middle of next year, though infants may not be approved until the end of 2021. > Dr. Moncef Slaoui, the White House vaccine czar, tells @jaketapper that he expects children will be able to receive a coronavirus vaccine some time in the middle of next year. "We need to run those clinical trials on an expedited basis." CNNSOTU pic.twitter.com/WlOUxKA3RN> > -- State of the Union (@CNNSotu) November 22, 2020More stories from theweek.com There's a very simple, extremely plausible reason Trump won't admit Biden won I was wrong about Mitt Romney Biden is stealing the spotlight. Trump can't stand it.

  • China beat the coronavirus with science and strong public health measures, not just with authoritarianism

    I live in a democracy. But as Thanksgiving approaches, I find myself longing for the type of freedom I am seeing in China. People in China are able to move around freely right now. Many Americans may believe that the Chinese are able to enjoy this freedom because of China’s authoritarian regime. As a scholar of public health in China, I think the answers go beyond that.My research suggests that the control of the virus in China is not the result of authoritarian policy, but of a national prioritization of health. China learned a tough lesson with SARS, the first coronavirus pandemic of the 21st century. How China flattened its curveBarely less than a year ago, a novel coronavirus emerged in Wuhan, China, with 80,000 cases identified within three months, killing 3,000 people. In late January 2020, the Chinese government decided to lock down this city of 11 million people. All transportation to and from the city was stopped. Officials further locked down several other cities in Hubei Province, eventually quarantining over 50 million people.By the beginning of April, the Chinese government limited the spread of the virus to the point where they felt comfortable opening up Wuhan once again. Seven months later, China has confirmed 9,100 additional cases and recorded 1,407 more deaths due to the coronavirus. People in China travel, eat in restaurants and go into theaters, and kids go to school without much concern for their health. Juxtapose that to what we are experiencing in the U.S. To date, we have confirmed over 11 million cases, with the last 1 million recorded in just the last one week alone. In September and October, friends from China sent me pictures of food from all over the country as they traveled around to visit friends and family for the mid-autumn festival and then the seven-day National Day vacation week. I envied them then and envy them even more now as Americans prepare and wonder how we will celebrate Thanksgiving this year. What China learned from SARSWe Americans are told that the freedoms Chinese now enjoy come at the expense of being subject to a set of draconian public health policies that can be instituted only by an authoritarian government. But they also have the experience of living through a similar epidemic.SARS broke out in November of 2002 and ended in May of 2003, and China was anything but prepared for its emergence. It didn’t have the public health infrastructure in place to detect or control such a disease, and initially decided to prioritize politics and economy over health by covering up the epidemic. This didn’t work with such a virulent disease that started spreading around the world. After being forced to come to terms with SARS, China’s leaders eventually did enforce quarantine in Beijing and canceled the week-long May Day holiday of 2003. This helped to end the pandemic within a few short months, with minimal impact. SARS infected approximately 8,000 worldwide and killed about 800, 65% of which occurred in China and Hong Kong. The Chinese government learned from SARS the important role public health plays in protecting the nation. Following SARS, the government improved training of public health professionals and developed one of the most sophisticated disease surveillance systems in the world. While caught off guard for this next big coronavirus outbreak in December 2019, the country quickly mobilized its resources to bring the epidemic almost to a halt inside its borders within three months. What can the US learn from China?Knowing that there were no safe or proven treatments or an effective vaccine, China relied on proven nonpharmaceutical interventions to conquer the epidemic. First and foremost was containing the virus through controlling the sources of infection and blocking transmission. This was accomplished through early detection (testing), isolation, treatment and tracing the close contacts of any infected individual. This strategy was aided by the three field hospitals (fancang) the government built to isolate patients with mild to moderate symptoms from their families. Strict quarantine measures were also central to preventing the spread of this epidemic, as it was with the SARS epidemic in 2003. This was paired with compulsory mask-wearing, promotion of personal hygiene (hand-washing, home disinfection, ventilation), self-monitoring of body temperature, universal compulsory stay-at-home orders for all residents, and universal symptom surveys conducted by community workers and volunteers. What else could the US have done to be prepared?SARS exposed serious weaknesses in China’s public health system and prompted its government to reinvent its public health system. COVID-19 has exposed similar shortcomings in the U.S. public health system. To date, however, the current administration has taken the exact opposite approach, devastating our public health system. The Trump administration made major cuts to the budgets of the National Institutes of Health and Centers for Disease Control and Prevention. The last budget submitted by the Trump administration in February 2020, as the pandemic was beginning, called for an additional reduction of US$693 million to the CDC budget. This affected our ability to prepare for a pandemic outbreak. In the past, this preparation included international partnerships to help detect disease before it reached our shores. For example, the CDC built up partnerships with China following the SARS epidemic, to help contain the emergence of infectious disease coming from the region. At one point the CDC had 10 American experts working on the ground in China and 40 local Chinese staff, who mostly concentrated on infectious disease. Trump started slashing these positions shortly after taking office, and by the time COVID-19 broke out, those programs were whittled down to a skeleton staff of one or two. [Research into coronavirus and other news from science Subscribe to The Conversation’s new science newsletter.]The Declaration of Alma Ata guaranteed health for all, and not just health for people governed under a specific type of bureaucratic system. The U.S. has been, and can be, just as dedicated to protecting the health of its people as China under its authoritarian government. We demonstrated this during the Ebola epidemic, with the launch of a whole government effort coordinated by Ron Klain, who has been appointed White House chief of staff under President-elect Biden.This effort, which included a coordinated response with both African nations and China, improved preparedness within the U.S. and ultimately helped to save hundreds of thousands of lives around the world. A reduction in funding for our public health infrastructure, under the Trump administration, was a divestment in the health of the American people and should not have happened. A new administration that places public health at the helm, once again, will I hope prove to us that health is not just something that can be protected under an authoritarian government, but is in fact a right for all.This article is republished from The Conversation, a nonprofit news site dedicated to sharing ideas from academic experts. It was written by: Elanah Uretsky, Brandeis University.Read more: * Poor US pandemic response will reverberate in health care politics for years, health scholars warn * Experts agree that Trump’s coronavirus response was poor, but the US was ill-prepared in the first placeElanah Uretsky does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

  • Mexico denies deal made to nab capo in return for ex-defense minister

    Mexican President Andres Manuel Lopez Obrador on Monday denied that Mexico had agreed to capture a cartel leader for the United States in order to secure the return of ex-defense minister Salvador Cienfuegos from U.S. custody. Reuters reported last week that Mexico agreed with U.S. Attorney General William Barr to seek the arrest of a high-level Mexican drug cartel leader as part of a deal to get U.S. drug trafficking charges against Cienfuegos dropped. "There is no deal in the shadows," Lopez Obrador said at his regular news conference, referring to the Reuters story as well as other media reports that Mexico had threatened to expel U.S. Drug Enforcement Administration agents over Cienfuegos' arrest.

  • Biden team is reportedly pushing congressional Democrats to strike an immediate stimulus deal with Republicans to stave off a renewed recession

    The surge in virus cases is causing another wave of restrictions and closures that experts say could damage the economic recovery.

  • US provides missiles, renews pledge to defend Philippines

    U.S. President Donald Trump’s administration provided precision-guided missiles and other weapons to help the Philippines battle Islamic State group-aligned militants and renewed a pledge to defend its treaty ally if it comes under attack in the disputed South China Sea. National Security Adviser Robert O’Brien represented Trump in Monday’s ceremony at the Department of Foreign Affairs in Manila, where he announced the delivery of the missiles and bombs to the Philippine military. Trump pledged to provide the $18 million worth of missiles in a phone conversation with Philippine President Rodrigo Duterte in April, Foreign Secretary Teodoro Locsin Jr. said.

  • Amid surge in coronavirus cases, L.A. County suspends outdoor dining

    With the number of new coronavirus cases soaring in Los Angeles County, public health officials announced on Sunday that starting Wednesday at 10 p.m., outdoor dining at restaurants, bars, wineries, and breweries in the county will be suspended for at least three weeks."The persistent high number of cases requires additional safety measures that limit mixing in settings where people are not wearing masks," Barbara Ferrer, the L.A. County health director, said in a statement.The establishments will only be allowed to offer takeout and delivery, with wineries and breweries also permitted to sell their products. The restaurant industry has been hit hard in L.A. County, and most spots have enhanced their patios or turned their parking lots into dining areas, adding tables, tents, and heaters in order to attract more customers.Since late October, the number of coronavirus cases has been accelerating faster than it did in July, the county's peak. Last week, health officials said if the five-day average of new cases topped 4,000 or if COVID-19 hospitalizations reached 1,750 per day, outdoor dining would be put on hold. On Sunday, the five-day average hit 4,097. There were 1,473 confirmed coronavirus patients hospitalized in L.A. County on Saturday, up about 92 percent from a month before, the Los Angeles Times reports. As of Sunday, L.A. County has recorded 364,520 coronavirus cases and 7,438 deaths.Michael Simhai owns the restaurant Della Terra in Los Angeles, and he told the Times the outdoor dining suspension will "be horrible for my staff. They can't get unemployment. ... They work paycheck to paycheck. What are we going to do?" Simhai said he purchased heaters and other items for his patio to keep diners warm this winter, "thinking that in the holiday season, we'd make money. All that money I spent, I can't recover it." Read more at the Los Angeles Times.More stories from theweek.com There's a very simple, extremely plausible reason Trump won't admit Biden won I was wrong about Mitt Romney Biden is stealing the spotlight. Trump can't stand it.

  • Wong, Chow and Lam: Three young Hong Kong activists facing jail

    Three prominent Hong Kong activists are facing jail after pleading guilty on Monday to inciting an "illegal assembly" outside the city's main police station during last year's huge pro-democracy protests.

  • Australian PM says misinterpretation of interests behind China tension

    Tension between Australia and China has been driven by incorrect assumptions shaped by rivalry between China and the United States but Australia has its own interest and independent views, Prime Minister Scott Morrison said on Monday. Australia's relationship with China soured in 2018 when it became the first country to publicly ban China’s Huawei from its 5G network, and worsened this year when Australia called for an enquiry into the origins of the novel coronavirus.

  • Wisconsin police arrest 15-year-old boy for Mayfair Mall shooting, say 'bullets started flying' during altercation

    While witnesses described the shooter as a white man in his 20s or 30s, Wauwatosa Police Chief Barry Weber said the suspect is an Hispanic teenager.